Allergy Therapeutics Deepens Real-World Data on Grassmuno® With New GRASS Study

Allergy Therapeutics (GB:AGY) announced an update on their ongoing clinical study.

The GRASS (Grass MATA MPL Real-world Assessment Study) is a prospective, open, multi-center observational study run by Allergy Therapeutics (AGY). It tracks how adults with grass pollen allergy use Grassmuno® in everyday clinics, aiming to capture real-world benefits, side effects, and treatment stickiness that trial data may miss.

The treatment under review is Grassmuno®, a pre-seasonal allergy shot given under the skin. It is designed to reduce moderate to severe grass pollen allergy symptoms and improve quality of life during the pollen season.

The study is observational, so doctors follow their usual care and do not assign patients randomly. There is no blinding; the goal is to watch a real-world cohort over time and see how Grassmuno® performs outside tightly controlled trials.

The trial was first submitted on 28 January 2026, marking the formal launch of patient tracking. The latest update on 19 March 2026 confirms that the protocol and status are current and that the sponsor is actively managing the study.

The study is now in recruiting status, so key primary and final completion dates are still ahead. Once these dates are set and met, investors will gain clearer visibility on long-term use patterns and any safety or adherence flags.

For AGY, this update supports the de-risking of its allergy franchise by adding real-world evidence behind an existing product rather than a high-risk new asset. That can foster steadier investor sentiment, supporting valuation even if near-term revenue growth remains modest.

In a competitive allergy market that includes players focused on tablets and sprays, robust real-world data can help Grassmuno® defend or grow share among specialists. Strong outcomes on compliance and patient benefit could also support pricing and reimbursement talks in key European markets.

Overall, the update signals ongoing investment in clinical evidence rather than a binary catalyst, so share price moves may be gradual and tied to future data reads. The study is currently recruiting and updated, with fuller details available on the ClinicalTrials portal.

To learn more about GB:AGY’s potential, visit the Allergy Therapeutics drug pipeline page.